Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Loong · SciRah

Researcher profile · Semantic Scholar

H. Loong

Share profile

H. Loong — researcher profile on SciRah

h-index: 19
Works: 71
Citations: 2,765

Most-cited papers

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
R. Doebele, A. Drilon, L. Paz-Ares, S. Siena +34 more
2019The Lancet Oncology1,438 citations Open access
Semantic Scholar
Overview of current systemic management of EGFR-mutant NSCLC
Wei-Hang Hsu, Jie Yang, T. Mok, H. Loong
2018Annals of Oncology351 citations Open access
Semantic Scholar
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
A. Desai, J. Gainor, A. Hegde, A. Schram +20 more
2021Nature Reviews Clinical Oncology120 citations Open access
Semantic Scholar
A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
A. Drilon, V. Subbiah, G. Oxnard, T. Bauer +16 more
2018105 citations
Semantic Scholar
Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC.
E. Felip, F. De Braud, M. Maur, H. Loong +14 more
2020Journal of Thoracic Oncology59 citations Open access
Semantic Scholar
An international real-world analysis of efficacy and safety of lorlatinib via early or expanded access programs in patients with TKI-refractory ALK+ or ROS1+ NSCLC.
Viola W. Zhu, Yen-Ting Lin, Dong-Wan Kim, H. Loong +10 more
2020Journal of Thoracic Oncology48 citations Open access
Semantic Scholar
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
B. Cho, Chao-Hua Chiu, E. Massarelli, G. Buchschacher +13 more
2023Lung Cancer42 citations Open access
Semantic Scholar
Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer
S. Lau, U. Batra, T. Mok, H. Loong
2019Drugs41 citations
Semantic Scholar
Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer
H. Loong, S. Kwan, T. Mok, Y. Lau
2018Current Treatment Options in Oncology41 citations
Semantic Scholar
BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.
P. Schőffski, B. Cho, A. Italiano, H. Loong +12 more
202140 citations
Semantic Scholar
Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).
E. Felip, F. De Braud, M. Maur, H. Loong +11 more
201738 citations
Semantic Scholar
KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).
P. Cassier, C. Dooms, A. Gazzah, E. Felip +16 more
2023Journal of Clinical Oncology35 citations
Semantic Scholar
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
H. Loong, Carlos K. H. Wong, L. K. S. Leung, Praveen Dhankhar +9 more
2019PharmacoEconomics - Open28 citations Open access
Semantic Scholar
OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer
G. Oxnard, V. Subbiah, K. Park, T. Bauer +23 more
2018Journal of Thoracic Oncology27 citations Open access
Semantic Scholar
Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.
S. Siena, R. Doebele, A. Shaw, C. Karapetis +15 more
2019Journal of Clinical Oncology25 citations
Semantic Scholar
Phase III study of selpercatinib vs chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer.
B. Solomon, Cai-Cun Zhou, A. Drilon, Keunchil Park +13 more
2020Future Oncology24 citations Open access
Semantic Scholar
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
B. Cho, Shun Lu, M. Lee, Zheng-Bo Song +19 more
2025Nature Medicine23 citations
Semantic Scholar
Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer
L. Leung, T. Mok, H. Loong
2012Therapeutic Advances in Medical Oncology23 citations Open access
Semantic Scholar
NTRK gene fusion testing and management in lung cancer.
M. Repetto, Marina Chiara Garassino, H. Loong, F. López-Ríos +7 more
2024Cancer Treatment Reviews21 citations Open access
Semantic Scholar
Crizotinib in the management of advanced-stage non-small-cell lung cancer.
H. Loong, Kevin K. S. Mok, L. Leung, T. Mok
2015Future Oncology19 citations
Semantic Scholar
Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations
B. Solomon, H. Loong, Y. Summers, Z. Thomas +6 more
2022ESMO Open18 citations Open access
Semantic Scholar
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer
B. Solomon, Cai-Cun Zhou, A. Drilon, Keunchil Park +14 more
202118 citations
Semantic Scholar
Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study.
N. Girard, Tae Min Kim, H. R. Kim, H. Loong +16 more
2024Journal of Clinical Oncology16 citations
Semantic Scholar
Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
V. Subbiah, J. Gainor, G. Oxnard, D. Tan +14 more
2020Journal of Clinical Oncology15 citations
Semantic Scholar
Personalized medicine for non-small-cell lung cancer
T. Mok, Qing Zhou, L. Leung, H. Loong
2010Expert Review of Anticancer Therapy15 citations
Semantic Scholar
Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors
D. Tan, Toshio Shimizu, B. Solomon, R. Heist +19 more
2022Cancer Research13 citations
Semantic Scholar
Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small cell lung cancer.
Koichi Goto, G. Oxnard, D. S. Tan, H. Loong +16 more
2020Journal of Clinical Oncology12 citations
Semantic Scholar
Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?
T. Mok, H. Loong
2016The Lancet10 citations
Semantic Scholar
SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2 -mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease.
H. Loong, Lin Li, Lin Wu, Tae Min Kim +16 more
2025Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Challenges and insights of early phase oncology drug development in the Asia-Pacific region.
H. Loong, D. Tan, Toshio Shimizu
2019Chinese Clinical Oncology9 citations Open access
Semantic Scholar
Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non–Small‐cell Lung Cancer in Asia
H. Loong, V. Raymond, Y. Shiotsu, D. Chua +5 more
2018Clinical Lung Cancer9 citations
Semantic Scholar
Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC).
B. Cho, C. Chiu, E. Massarelli, G. Buchschacher +10 more
2023Journal of Clinical Oncology8 citations Open access
Semantic Scholar
CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression.
Wesley K. Y. Wong, Kevin K. S. Mok, G. Tsui, Olivia H. Chen +13 more
2025Clinical Lung Cancer7 citations Open access
Semantic Scholar
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.
Alissa J Cooper, A. Drilon, J. Rotow, Stephen V. Liu +16 more
2023Journal of Clinical Oncology7 citations Open access
Semantic Scholar
KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.
F. Cappuzzo, G. Castro, J. Kang, Yi-Long Wu +8 more
2023Journal of Clinical Oncology7 citations
Semantic Scholar
Local ablative radiotherapy on oligo‐progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non–small cell lung cancer patients: A longer cohort
F. Mok, M. Tong, H. Loong, T. Mok
2022Asia-Pacific Journal of Clinical Oncology7 citations
Semantic Scholar
LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIA RET fusion-positive NSCLC.
R. Rajaram, L. Sholl, S. Dacic, J. Goldman +11 more
2022Journal of Clinical Oncology6 citations
Semantic Scholar
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
A. Desai, J. Gainor, A. Hegde, A. Schram +20 more
2021Nature Reviews Clinical Oncology6 citations Open access
Semantic Scholar
A REVELation in non-small-cell lung cancer treatment?
T. Mok, H. Loong
2014The Lancet6 citations
Semantic Scholar
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study
P. Schöffski, A. Gazzah, J. Trigo, A. Italiano +9 more
2025ESMO Open4 citations Open access
Semantic Scholar
Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease
Molly S. C. Li, Kirsty W. C. Lee, Kevin K. S. Mok, H. Loong +12 more
2024JTO Clinical and Research Reports4 citations Open access
Semantic Scholar
Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.
Jia Liu, J. Beal, N. Coleman, B. Ma +6 more
2026Journal of Clinical Oncology3 citations
Semantic Scholar
Overcoming the impact of the COVID‐19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium
Toshio Shimizu, Dong-Wan Kim, H. Loong, Chia-Chi Lin +4 more
2021Asia-Pacific Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
A. Tan, H. Loong, G. Ho, A. Seet +8 more
2019Annals of Oncology3 citations Open access
Semantic Scholar
KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
P. Cassier, C. Dooms, A. Gazzah, E. Felip +16 more
2024International Journal of Radiation Oncology, Biology, Physics2 citations
Semantic Scholar
Efficacy and safety of 1L selpercatinib in RET fusion-positive NSCLC: LIBRETTO-431 East Asian subgroup analysis.
Ying Cheng, H. Loong, Cai-Cun Zhou, K. Nishino +9 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar
1349P Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases
M. Li, K. Mok, L. Chan, K. Lee +10 more
2023Annals of Oncology2 citations
Semantic Scholar
P2.09-24 Risk of Recurrent Interstitial Lung Disease (ILD) from EGFR TKI Rechallenge after Osimertinib Induced ILD
Ms Li, K. Lee, H. Loong, K. Lam +10 more
2023Journal of Thoracic Oncology2 citations Open access
Semantic Scholar
264P Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with NTRK fusion-positive (fp) solid tumours and ROS1-fp non-small cell lung cancer (NSCLC)
S. Lu, Y. Fan, C.-H. Chiu, Y. Yu +11 more
2022Annals of Oncology2 citations Open access
Semantic Scholar
Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.
B. Solomon, H. Loong, Y. Summers, Z. Thomas +6 more
20202 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Drilon×13
Invite
A. Drilon — researcher profile on SciRah
T. Mok×10
Invite
T. Mok — researcher profile on SciRah
V. Subbiah×7
Invite
V. Subbiah — researcher profile on SciRah
B. Solomon×7
Invite
B. Solomon — researcher profile on SciRah

×6

Invite

D. Tan — researcher profile on SciRah

Invite

B. Besse — researcher profile on SciRah

Invite

J. Gainor — researcher profile on SciRah

Invite

E. Felip — researcher profile on SciRah

Invite

F. De Braud — researcher profile on SciRah

Invite

B. Cho — researcher profile on SciRah

Invite

A. Farago — researcher profile on SciRah

Stephen V. Liu×4

Invite

Stephen V. Liu — researcher profile on SciRah